Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (71-80 of 210) with videos related to

Pageof 21
Sort By:
Journal of Surgical Oncology|February 11, 2009
The influence of a gene expression profile on breast cancer decisionsLeonard R Henry, Alexander Stojadinovic, Sandra M Swain, et al.
Oncology Reports|January 5, 2007
Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarraySherry X Yang, Stephen M Hewitt, Seth M Steinberg, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
A critical review of the enrollment of black patients in cancer clinical trialsDeliya R Banda, Diane St Germain, Worta McCaskill-Stevens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancerSherry X Yang, Seth M Steinberg, Dat Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancerJosé Baselga, Javier Cortés, Seock-Ah Im, et al.
Pharmacogenomics|January 19, 2022
Evaluation of a longitudinal pharmacogenomics education on pharmacist knowledge in a multicampus healthcare systemAndrew J Lee, Adrian C Hui, Alexander D Walker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapyJennifer A Low, Arlene W Berman, Seth M Steinberg, et al.
Clinical Breast Cancer|December 31, 2005
A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancerNeelima Denduluri, Antoinette R Tan, Janice Walshe, et al.
Pharmacogenomics|November 9, 2023
Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectivesMeghna Bhatt, Beth N Peshkin, Sadaf Kazi, et al.
Breast Cancer Research and Treatment|October 17, 2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)David Miles, José Baselga, Dino Amadori, et al.
Pageof 21

Showing results (71-80 of 210) with videos related to

Sort By:
Pageof 21
Journal of Surgical Oncology|February 11, 2009
The influence of a gene expression profile on breast cancer decisionsLeonard R Henry, Alexander Stojadinovic, Sandra M Swain, et al.
Oncology Reports|January 5, 2007
Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarraySherry X Yang, Stephen M Hewitt, Seth M Steinberg, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
A critical review of the enrollment of black patients in cancer clinical trialsDeliya R Banda, Diane St Germain, Worta McCaskill-Stevens, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancerSherry X Yang, Seth M Steinberg, Dat Nguyen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancerJosé Baselga, Javier Cortés, Seock-Ah Im, et al.
Pharmacogenomics|January 19, 2022
Evaluation of a longitudinal pharmacogenomics education on pharmacist knowledge in a multicampus healthcare systemAndrew J Lee, Adrian C Hui, Alexander D Walker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapyJennifer A Low, Arlene W Berman, Seth M Steinberg, et al.
Clinical Breast Cancer|December 31, 2005
A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancerNeelima Denduluri, Antoinette R Tan, Janice Walshe, et al.
Pharmacogenomics|November 9, 2023
Pharmacogenomic testing in oncology: a health system's approach to identify oncology provider perspectivesMeghna Bhatt, Beth N Peshkin, Sadaf Kazi, et al.
Breast Cancer Research and Treatment|October 17, 2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)David Miles, José Baselga, Dino Amadori, et al.
Pageof 21